Statement Of Cash Flows [Abstract]

BioArctic - Filing #678259

Concept 2023-01-01 to
2023-12-31
As at
2023-12-31
As at
2023-01-01
As at
2022-12-31
2022-01-01 to
2022-12-31
As at
2022-01-01
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Profit (loss)
252 640 SEK
17 336 SEK
Adjustments to reconcile profit (loss) [abstract]
Adjustments for decrease (increase) in other operating receivables
11 979 SEK
2 414 SEK
Adjustments for increase (decrease) in other operating payables
25 132 SEK
27 328 SEK
Other adjustments for non-cash items
9 895 SEK
41 340 SEK
Cash flows from (used in) operations
309 694 SEK
31 637 SEK
Interest paid, classified as operating activities
379,000 SEK
751,000 SEK
Interest received, classified as operating activities
34 228 SEK
2 535 SEK
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
7 443 SEK
12 746 SEK
Other inflows (outflows) of cash, classified as investing activities
500 042 SEK
18,000 SEK
Cash flows from (used in) investing activities
507 485 SEK
12 763 SEK
Cash flows from (used in) financing activities [abstract]
Payments of lease liabilities, classified as financing activities
917,000 SEK
8 793 SEK
Dividends paid, classified as financing activities
14 982 SEK
5 985 SEK
Cash flows from (used in) financing activities
14 064 SEK
2 808 SEK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
183 727 SEK
47 209 SEK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
10 093 SEK
4 190 SEK
Cash and cash equivalents
611 567 SEK
805 386 SEK
805 386 SEK
848 405 SEK

Talk to a Data Expert

Have a question? We'll get back to you promptly.